BMPR2 and pulmonary arterial hypertension: Another therapeutic agent that can promote expression of BMPRII pathway effectors is tyrphostin-AG1296, a small-molecule tyrosine kinase inhibitor identified by screening compounds for improved survival of ECs from PAH patients (148).